VEGF expression and possible response to angiogenesis inhibitor bevacizumab ASPS mets
Posted: Thu Jan 28, 2016 8:22 am
Vascular-endothelial-growth-factor (VEGF) expression and
possible response to angiogenesis inhibitor bevacizumab in
metastatic alveolar soft part sarcoma
Amedeo A Azizi,* Christine Haberler,* Thomas Czech, Astrid Gupper, Daniela Prayer, Helene Breitschopf, Till Acker, Irene Slav
The decision to use antiangiogenic treatment for our
patient was based on three factors: (1) the high
vascularisation of the tumour, (2) the ineffectiveness of
cytotoxic chemotherapy regimens in our patient, and
(3) the known benefit of antiangiogenic treatment in
tumours that are highly vascularised (eg, angioblastoma)3
and slow-growing (eg, renal-cell carcinomas).4
Antiangiogenic drugs can be classifi ed according to their
mechanism of action—eg, those inhibiting the breakdown
of basement membrane, endothelial-cell migration and
proliferation, cell-adhesion molecules, or angiogenic
growth factors or their receptors.5,6 Additional compounds
with established antineoplastic or antiproliferative
functions, such as thalidomide or inter feron alfa-2b, have
been reported to have anti angiogenic activities.7,8
http://cureasps.org/library/9_Avastin_Vienna_06.pdf
http://oncology.thelancet.com Vol 7 June 2006
possible response to angiogenesis inhibitor bevacizumab in
metastatic alveolar soft part sarcoma
Amedeo A Azizi,* Christine Haberler,* Thomas Czech, Astrid Gupper, Daniela Prayer, Helene Breitschopf, Till Acker, Irene Slav
The decision to use antiangiogenic treatment for our
patient was based on three factors: (1) the high
vascularisation of the tumour, (2) the ineffectiveness of
cytotoxic chemotherapy regimens in our patient, and
(3) the known benefit of antiangiogenic treatment in
tumours that are highly vascularised (eg, angioblastoma)3
and slow-growing (eg, renal-cell carcinomas).4
Antiangiogenic drugs can be classifi ed according to their
mechanism of action—eg, those inhibiting the breakdown
of basement membrane, endothelial-cell migration and
proliferation, cell-adhesion molecules, or angiogenic
growth factors or their receptors.5,6 Additional compounds
with established antineoplastic or antiproliferative
functions, such as thalidomide or inter feron alfa-2b, have
been reported to have anti angiogenic activities.7,8
http://cureasps.org/library/9_Avastin_Vienna_06.pdf
http://oncology.thelancet.com Vol 7 June 2006